Skip to main content
. 2018 Nov 25;38:100–112. doi: 10.1016/j.ebiom.2018.11.004

Fig. 6.

Fig. 6

Uptake of oncogenic miR-1246 by tumor-associated macrophages in the tumor microenviroment. a. F4/80 macrophage marker was used to evaluate the macrophage levels upon treatment with miR-1246 inhibitor or CTL miRNA inhibitor alone or in combination with paclitaxel in an in vivo model. b. Levels of Cav1 and p-gp levels were detected in THP-1, differentiated THP-1 (M0), M1 and M2 type macrophages by western blotting. c. qPCR analysis of miR-1246 in M2-type macrophages cultured with or without SKOV3-ip1 OC cells. d. qPCR analysis of Cav1 in M2-type macrophages cultured with or without SKOV3-ip1 OC cells. e. qPCR analysis of Cav1 in M2-type macrophages alone, M2-type macrophages treated with exosomes isolated from SKOV3-ip1 OC cells and M2-type macrophages treated with exosomes isolated from SKOV3-ip1 cells that were pretreated with GW4869 exosome inhibitor. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (t-test), data are presented as mean ± SD.